| | |||||
| lung cancer | |||||
| 新闻 | |||||
| Sevabertinib Given FDA Priority Review for HER2+ NSCLC - Oncology Nursing News The oral TKI sevabertinib has been granted priority review for use in patients harboring HER2 mutations in non-small cell lung cancer.
| |||||
| 查看更多结果 | 修改此快讯 | |||||
| 您收到此电子邮件是因为您订阅了Google快讯。 |
以RSS Feed的形式接收此快讯 |
| 发送反馈 |
No comments:
Post a Comment